Etienne B, Pérol M, Nesme P, Vuillermoz S, Robinet G, Guérin J C
Service de Pneumologie, Hôpital de la Croix-Rousse, Lyon.
Rev Mal Respir. 1998 Apr;15(2):199-203.
Docetaxel, a new chemotherapeutic agent, has demonstrated activity in non-small cell lung cancer and breast cancer. Toxicities associated with treatment using docetaxel include hypersensitivity reactions and fluid retention, which can be prevented by pretreatment with corticosteroids. We describe herein two cases of acute interstitial pneumonitis after administration of docetaxel to patients suffering from metastatic non-small cell lung cancer. A pulmonary toxicity of docetaxel from an hypersensitivity reaction is likely because of symptoms course, radiological demonstration of an interstitial pneumonitis, lack of an infectious etiology and of clinical response to antibiotic treatment, and rapid recovery with corticosteroids. This unusual pulmonary toxicity has been rarely described with docetaxel, as transient pulmonary infiltrates have been observed during treatment with paclitaxel. The possibility of an hypersensitivity pneumonitis must be taken into account when a patient with docetaxel treatment presents pulmonary infiltrates.
多西他赛是一种新型化疗药物，已在非小细胞肺癌和乳腺癌中显示出活性。使用多西他赛治疗相关的毒性包括过敏反应和液体潴留，可通过使用皮质类固醇进行预处理来预防。我们在此描述了两例转移性非小细胞肺癌患者在使用多西他赛后发生急性间质性肺炎的病例。多西他赛引起的肺部毒性可能是由过敏反应导致的，这是基于症状过程、间质性肺炎的影像学表现、缺乏感染病因以及对抗生素治疗无临床反应，并且使用皮质类固醇后迅速恢复。这种不寻常的肺部毒性在多西他赛治疗中很少被描述，而在紫杉醇治疗期间曾观察到短暂的肺部浸润。当接受多西他赛治疗的患者出现肺部浸润时，必须考虑过敏性肺炎的可能性。
